Literature DB >> 2208787

How does HLA-B27 confer susceptibility to inflammatory arthritis?

J S Gaston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2208787      PMCID： PMC1535163          DOI： 10.1111/j.1365-2249.1990.tb05394.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  24 in total

1.  A Yersinia pseudotuberculosis protein which cross-reacts with HLA-B27.

Authors:  J H Chen; D H Kono; Z Yong; M S Park; M M Oldstone; D T Yu
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

2.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

3.  Identification of a 2-Md plasmid from Shigella flexneri associated with reactive arthritis.

Authors:  H Stieglitz; S Fosmire; P Lipsky
Journal:  Arthritis Rheum       Date:  1989-08

4.  HLA-B27 in inbred and non-inbred transgenic mice. Cell surface expression and recognition as an alloantigen in the absence of human beta 2-microglobulin.

Authors:  J D Taurog; L Lowen; J Forman; R E Hammer
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

5.  Studies of humoral and cell-mediated immunity to peptides shared by HLA-27.1 and Klebsiella pneumoniae nitrogenase in ankylosing spondylitis.

Authors:  N Tsuchiya; G Husby; R C Williams
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

6.  In vitro mutagenesis of HLA-B27. Substitution of an unpaired cysteine residue in the alpha 1 domain causes loss of antibody-defined epitopes.

Authors:  J D Taurog; F A el-Zaatari
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Yersinia antigens in synovial-fluid cells from patients with reactive arthritis.

Authors:  K Granfors; S Jalkanen; R von Essen; R Lahesmaa-Rantala; O Isomäki; K Pekkola-Heino; R Merilahti-Palo; R Saario; H Isomäki; A Toivanen
Journal:  N Engl J Med       Date:  1989-01-26       Impact factor: 91.245

Review 8.  The thymus selects the useful, neglects the useless and destroys the harmful.

Authors:  H von Boehmer; H S Teh; P Kisielow
Journal:  Immunol Today       Date:  1989-02

9.  Chlamydia trachomatis and reactive arthritis: the missing link.

Authors:  A Keat; B Thomas; J Dixey; M Osborn; C Sonnex; D Taylor-Robinson
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

10.  Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease.

Authors:  P L Schwimmbeck; D T Yu; M B Oldstone
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307
View more
  5 in total

1.  Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies.

Authors:  A F Geczy; J S Sullivan
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

2.  Extended repertoire of permissible peptide ligands for HLA-B*2702.

Authors:  M Raghavan; J A Lebrón; J L Johnson; P J Bjorkman
Journal:  Protein Sci       Date:  1996-10       Impact factor: 6.725

3.  Reactive arthritis-associated bacteria can stimulate lymphocyte proliferation in non-exposed individuals and newborns.

Authors:  F Chieco-Bianchi; K Hedley; T Weissensteiner; G S Panayi; G H Kingsley
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

4.  MHC restriction of synovial fluid lymphocyte responses to the triggering organism in reactive arthritis. Absence of a class I-restricted response.

Authors:  A B Hassell; D Pilling; D Reynolds; P F Life; P A Bacon; J S Gaston
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

Review 5.  Chronic sequelae of foodborne disease.

Authors:  J A Lindsay
Journal:  Emerg Infect Dis       Date:  1997 Oct-Dec       Impact factor: 6.883
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.